Fecal microbiota transplant for C. difficile infection: Just say yes

Anaerobe. 2019 Dec:60:102109. doi: 10.1016/j.anaerobe.2019.102109. Epub 2019 Oct 20.

Abstract

The burden of Clostridium difficile associated diarrhea is a worrying clinical issue worldwide, mainly as regarding the high incidence of recurrences after standard antibiotic therapy and the risk for more severe clinical manifestations. For this reason, new and more effective therapies are needed for the treatment of recurrent episodes. Fecal microbiota transplantation seems to be a valid tool considering the mechanism of action and the growing number of studies that demonstrate its clinical efficacy.

Keywords: Antibiotics; Clostridium; Fecal microbiota transplantation.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile / physiology*
  • Clostridium Infections / diagnosis
  • Clostridium Infections / microbiology*
  • Clostridium Infections / therapy*
  • Enterocolitis, Pseudomembranous / diagnosis
  • Enterocolitis, Pseudomembranous / microbiology
  • Enterocolitis, Pseudomembranous / therapy
  • Fecal Microbiota Transplantation* / adverse effects
  • Fecal Microbiota Transplantation* / methods
  • Humans
  • Recurrence
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents